Bruker Corporation (NASDAQ:BRKR) Receives Average Rating of “Hold” from Brokerages

Bruker Corporation (NASDAQ:BRKR) has earned an average rating of “Hold” from the fifteen research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $50.3846.

A number of equities analysts recently issued reports on BRKR shares. Barclays decreased their price objective on Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Guggenheim boosted their price target on Bruker from $53.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Bank of America increased their price target on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th.

Insider Transactions at Bruker

In other Bruker news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This trade represents a 5.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last three months, insiders sold 11,000 shares of company stock worth $554,280. Company insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Rockefeller Capital Management L.P. raised its position in shares of Bruker by 741.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,522 shares of the medical research company’s stock worth $449,000 after purchasing an additional 8,391 shares during the period. Mengis Capital Management Inc. boosted its position in shares of Bruker by 2.0% in the 4th quarter. Mengis Capital Management Inc. now owns 57,220 shares of the medical research company’s stock valued at $2,696,000 after purchasing an additional 1,135 shares during the period. Pacer Advisors Inc. increased its stake in Bruker by 42.8% in the 4th quarter. Pacer Advisors Inc. now owns 20,822 shares of the medical research company’s stock worth $981,000 after purchasing an additional 6,242 shares in the last quarter. Alberta Investment Management Corp purchased a new position in Bruker in the 4th quarter worth about $1,748,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Bruker during the 4th quarter worth about $266,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Price Performance

BRKR stock opened at $33.72 on Monday. The stock has a market cap of $5.13 billion, a PE ratio of -224.80, a price-to-earnings-growth ratio of 2.02 and a beta of 1.19. The firm’s 50-day simple moving average is $40.06 and its 200 day simple moving average is $41.29. Bruker has a fifty-two week low of $28.53 and a fifty-two week high of $56.22. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The firm had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The company’s revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts predict that Bruker will post 2.69 EPS for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s payout ratio is presently -133.33%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.